Stockscreener 앱 받기
0.63
9.57%
0.055
시간 외 거래:
.62
-0.01
-1.59%
전일 마감가:
$0.575
열려 있는:
$0.56
하루 거래량:
956.11K
Relative Volume:
0.79
시가총액:
$1.29M
수익:
-
순이익/손실:
$-48.85M
주가수익비율:
-0.2727
EPS:
-2.31
순현금흐름:
$-46.25M
1주 성능:
+4.55%
1개월 성능:
-42.20%
6개월 성능:
-95.46%
1년 성능:
-99.51%
1일 변동 폭
$0.54
$0.65
1주일 범위
$0.4843
$0.65
52주 변동 폭
$0.4843
$136.80
Vincerx Pharma Inc Stock (VINC) Company Profile
명칭
Vincerx Pharma Inc
전화
650-800-6676
주소
260 SHERIDAN AVENUE, PALO ALTO
VINC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VINC
Vincerx Pharma Inc
|
0.63 | 1.29M | 0 | -48.85M | -46.25M | -2.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Vincerx Pharma Inc Stock (VINC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-01-14 | 개시 | H.C. Wainwright | Buy |
| 2021-12-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-11-01 | 개시 | SVB Leerink | Outperform |
| 2021-09-13 | 개시 | Laidlaw | Buy |
| 2021-08-25 | 개시 | B. Riley Securities | Buy |
Vincerx Pharma Inc 주식(VINC)의 최신 뉴스
VINC Stock Plummets to 52-Week Low of $0.48 Amid Steep Decline - Investing.com Australia
VINC Stock Plummets to 52-Week Low of $0.48 Amid Steep Decline By Investing.com - Investing.com South Africa
Vincerx Pharma (VINC) Projected to Post Quarterly Earnings on Friday - Defense World
Vincerx Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Vincerx Pharma Inc expected to post a loss of $3.40 a shareEarnings Preview - TradingView
Such Is The Power Of Vincerx Pharma Inc (NASDAQ: VINC) - Stocks Register
Vincerx Pharma plans reverse merger with QumulusAI By Investing.com - Investing.com Australia
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI - GlobeNewswire
VINC stock touches 52-week low at $0.73 amid sharp annual decline - Investing.com UK
Vincerx Pharma Plans Reverse Merger With AI Infrastructure Firm QumulusAI -March 18, 2025 at 09:40 am EDT - Marketscreener.com
Vincerx Pharma plans reverse merger with QumulusAI - Investing.com India
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI - Benzinga
Vincerx Pharma's $300M AI Transformation: QumulusAI Merger Creates New Computing Powerhouse - StockTitan
Vincerx Pharma Plunges After Scrapping Reverse Merger With Oqory And Vivaso - Nasdaq
Vincerx Pharma terminates reverse merger term sheet and evaluates strategic alternatives - MSN
Vincerx Pharma Terminates Reverse Merger Deal With Oqory - MarketWatch
Vincerx Pharma Explores Strategic Alternatives Post Merger Termination - TipRanks
Vincerx Pharma Announces Termination Of Reverse Merger Term Sheet -February 28, 2025 at 04:12 pm EST - Marketscreener.com
Vincerx Pharma announces termination of reverse merger term sheet - TipRanks
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - The Manila Times
Vincerx Pharma, Inc. Terminates Reverse Merger Agreement and Will Explore Strategic Alternatives - Nasdaq
Is Vincerx Pharma Running Out of Options? Merger Deal Collapses as Cash Dwindles - StockTitan
Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update - Defense World
VINC stock touches 52-week low at $1.17 amid market challenges - Investing.com Australia
VINC stock touches 52-week low at $1.17 amid market challenges By Investing.com - Investing.com South Africa
Vincerx Pharma Regains Compliance With Nasdaq Listing Rule 5550(A)(2) -February 18, 2025 at 05:27 pm EST - Marketscreener.com
Vincerx Pharma announces reverse stock split; shares drop - MSN
VINC stock touches 52-week low at $1.3 amid market challenges - Investing.com Australia
Vincerx Pharma, Inc. (NASDAQ:VINC) Sees Large Increase in Short Interest - MarketBeat
Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Rises By 1,022.5% - MarketBeat
VINC stock touches 52-week low at $1.62 amid market challenges - Investing.com Canada
Vincerx Pharma, Oqory highlight Phase 1a/1b data for OQY-3258 - TipRanks
Vincerx Pharma and Oqory reveal merger and cancer drug data - Investing.com
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258 - GlobeNewswire
Vincerx Pharma and Oqory reveal merger and cancer drug data By Investing.com - Investing.com UK
Revolutionary Cancer Treatment Achieves Unprecedented 80% Success Rate in Clinical Trial - StockTitan
Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn
Vincerx Pharma enters at-the-market equity offering deal - MSN
Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn
Vincerx Pharma (NASDAQ:VINC) Stock Quotes, Forecast and News Summary - Benzinga
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Vincerx Pharma files for $100M mixed securities shelf - MSN
Vincerx Pharma (NASDAQ:VINC) Implements 1-for-20 Reverse Stock Split - Defense World
Palo Alto's Vincerx Pharma plans reverse stock split amid merger plans - The Business Journals
Vincerx Pharma (VINC) Stock Price, News & Analysis - MarketBeat
Vincerx Pharma Inc. Announces Merger with Oqory - TipRanks
Vincerx Pharma, Inc. Announces Reverse Stock Split - The Manila Times
Vincerx Pharma Inc (VINC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):